AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$NBIX

MORROW GEORGE J sold $2.3M of NBIX

MORROW GEORGE J sold 15,000 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at an average of $155.73 ($144.98–$168.53, $2.34M total) across 12 trades over 2026-10-30 to 2026-11-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MORROW GEORGE J
Published Nov 3, 2026, 11:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NBIX
Bearish
high confidence
Mentioned
$NBIX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NBIXBearishLow
01

Why it matters

The disclosed sale may trigger short‑term price adjustments, but long‑term impact depends on company performance.

02

Market read

Primary insider sale news; modest relevance for traders monitoring NBIX.

03

What to watch

Potential upcoming clinical data releases could offset sell‑off pressure.

Relevance 5/10Novelty 4/10Timing: post‑market filing on 2026‑11‑03

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$NBIXBearishHigh confidence
Context

Director George Morrow sold 15,000 NBIX shares for $2.34M via a 10b5‑1 plan, reducing his stake to 10,386 shares.

Expected impact

likely modest downward pressure as investors price in the insider sell.

Evidence & confidence

A $2.3M sale by a director is material enough to influence short‑term sentiment, especially given the recent price range.

Market effects

Sector

Minimal; biotech sector unlikely to be broadly affected.

Regional

U.S. equity market only, no regional ripple.

Global

Low; limited to NBIX investors.

Counterpoint

What could challenge this read

The sale may be routine under a pre‑arranged plan and not indicative of company fundamentals.

Key entities

  • Company
    Neurocrine Biosciences Inc.

    Biotech firm developing treatments for neurological and endocrine disorders.

  • Individual
    George Morrow

    Director of Neurocrine Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NBIX insider trading history →

Related articles

$NBIXHighAI 8/10

NBIX Stock Jumps As Earnings Smash Estimates And Pipeline Expands

Neurocrine Biosciences Inc. (NBIX) stock rose 14.3% after strong Q3 earnings, with revenue of $1.12B (up from $794.9M YoY) and adjusted EPS of $3.29 (up from $2.17). The company also reported positive clinical data and expanded its pipeline, including a new Phase 2 trial for Alzheimer's treatment. Management raised FY26 revenue guidance to $2.9B–$2.925B, below consensus of $3.9B.

timothysykes.com
$NBIXHighAI 9/10

Why is Neurocrine Biosciences stock surging today?

Neurocrine Biosciences (NBIX) stock rose 15.1% after reporting Q3 adjusted earnings of $3.29 per share, beating estimates by 72%, and revenue of $1.12 billion, up 41% YoY. The company surpassed $1 billion in net product sales for the first time, driven by its top products. Analysts raised price targets, with Baird setting a $225 target. Management increased 2026 INGREZZA sales guidance to $2.9-$2.925 billion.

investing.com
$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

rttnews.com